Ultragenyx's Apazunersen Fails Phase 3 Aspire Trial in Angelman Syndrome

Update September 24, 2026: The September 19 UX111 decision referenced throughout this article has resolved — UX111 was approved September 17 as Fayuvi, the first-ever treatment for Sanfilippo syndrome type A. The “A CRL on September 19 stacks a second failure” and “September 19 event position” framing below did not play out: Ultragenyx got the approval, not a second failure.

Ultragenyx (RARE) said Wednesday afternoon that its Angelman syndrome therapy apazunersen failed the Phase 3 Aspire study, missing the trial’s primary endpoint and a key secondary endpoint. Shares closed at $26.53 on Wednesday, then fell about 46% in after-hours trading to roughly $14.

Apazunersen, formerly known as GTX-102, is an antisense oligonucleotide delivered intrathecally that is designed to reactivate the silenced paternal UBE3A allele. In Aspire it showed no significant benefit on the primary endpoint of change from baseline in the Bayley-4 cognitive raw score. It also missed the key secondary endpoint of net response in the Multidomain Responder Index (MDRI), which tracks improvement across five clinical domains. Ultragenyx said there were no differences between the treated and sham-control groups that could support efficacy, on either net response or the individual endpoints inside the MDRI. Safety in Aspire was consistent with the Phase 1/2 program.

The study enrolled nearly 130 patients with Angelman syndrome, a rare neurogenetic disorder that causes cognitive impairment, motor difficulties, and seizures. There are no approved therapies for the condition. The readout was the company’s central value driver, according to William Blair, which told investors the failure leaves Ultragenyx with no meaningful value inflection point over the next 12 months.

“We are disappointed by the Aspire result,” CEO Emil Kakkis said in a statement. “Even more, we are disappointed for the global patient community who has invested so much in early-stage research, working to bring a first-ever treatment to their children.”

Ultragenyx said it will evaluate the apazunersen program and “assess its planned operations to define and implement significant expense reductions” while it focuses on its commercial business. That business includes the August approval of Genglycos for glycogen storage disease type Ia and a September 19 PDUFA date for UX111 in Sanfilippo syndrome type A. A second apazunersen study, the Phase 2 Aurora basket trial, keeps enrolling with topline data expected in 2030, though William Blair said the Aspire failure could have negative implications for that program. The Angelman field still has other runners, including Oak Hill Bio’s rugonersen.

The stakes going in were high: apazunersen carried FDA Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track designations. The failure removes Ultragenyx’s nearest large revenue opportunity in a disease affecting roughly 60,000 people in commercially accessible geographies.

What to watch next: the September 19 UX111 decision, which analysts now frame as an incremental catalyst at best, and any details on the expense-reduction plan.

What It Means for the Trade

The 46% after-hours cut to roughly $14 is the market repricing Ultragenyx from a pipeline company into a commercial company with an uncertain growth story. The math is brutal but straightforward: apazunersen was the nearest large revenue driver, roughly 60,000 addressable Angelman patients in commercially accessible geographies with zero approved therapies, and William Blair now sees no meaningful value inflection for 12 months. When your central value driver fails a sham-controlled Phase 3 with no efficacy signal on any endpoint — primary, key secondary, or any individual MDRI domain — the readout does not leave room for a rescue narrative. Aspire did not miss narrowly; it showed nothing.

The honest question is what RARE is worth ex-Angelman. The commercial business includes the just-approved Genglycos in GSDIa, the September 19 UX111 PDUFA in Sanfilippo syndrome, and an established ultra-rare portfolio. That is a foundation — but it is a foundation the company was building underneath a pipeline story, and the expense reductions announced alongside the failure are management admitting the cost base was sized for the pipeline that no longer exists.

Mechanism and Market Context

Why did it fail? The target was sound — unsilencing the paternal UBE3A allele is the field’s leading disease-modifying hypothesis, and the antisense approach worked genetically in earlier studies. But mechanism correctness has never been the problem in Angelman; endpoint measurement is. Bayley-4 cognitive raw scores in a severely affected pediatric population move slowly and noisily, and a 48-week window may simply be too short to capture developmental change that parents report anecdotally. The sham-controlled design was scientifically correct and commercially unforgiving: it removed exactly the placebo inflation that made earlier open-label data look encouraging.

The field read-through is significant but differentiated. This failure does not kill the UBE3A hypothesis — it kills the “measurable cognition improvement in a one-year window” version of it. Companies with longer-duration endpoints, different delivery, or earlier intervention windows (Oak Hill Bio’s rugonersen among them) inherit the burden of proving the concept differently. For the antisense-CNS class broadly, Aspire joins a growing list of reminders that genetically rational programs still fail on translation.

Risks and What Could Go Wrong

1. UX111 is now the only near-term event, and it arrives in a market that just watched the bigger swing miss. A CRL on September 19 stacks a second failure into the same quarter.
2. The Aurora basket trial (2030 data) is a 2027-2030 cash drain with negative implications per William Blair; the market will discount it to near zero.
3. Balance-sheet burn. “Significant expense reductions” usually mean restructuring charges before they mean savings; watch the next quarterly cash number. The trade now is a September 19 event position sized small, or nothing. Catching this knife on “commercial support” alone has no catalyst behind it.

Source: Ultragenyx Phase 3 Aspire announcement; BioSpace coverage